Text Size
532 studies found for:    Open Studies | "Liver Neoplasms"

Modify this search | How to Use Search Results

Show Display Options
Rank Status Study
1 Recruiting IL-2 Expressing, Attenuated Salmonella Typhimurium in Unresectable Hepatic Spread
Conditions: Cancer of the Liver;   Liver Cancer;   Hepatoma;   Liver Neoplasms;   Biliary Cancer
Intervention: Biological: Salmonella typhimurium
2 Recruiting Sorafenib and TRC105 in Hepatocellular Cancer
Conditions: Hepatoma;   Liver Neoplasms;   Adenoma, Liver Cell;   Carcinoma, Hepatocellular
Interventions: Drug: TRC 105;   Drug: Sorafenib
3 Unknown † TheraSphere for Treatment of Unresectable Hepatocellular Carcinoma
Conditions: Hepatocellular Carcinoma;   Liver Cancer;   Liver Neoplasm;   Primary Liver Cancer
Intervention: Device: TheraSphere Yttrium-90 microspheres
4 Recruiting Sorafenib Tosylate Following a Liver Transplant in Treating Patients With Liver Cancer
Conditions: Adult Primary Hepatocellular Carcinoma;   Localized Resectable Adult Primary Liver Cancer;   Localized Unresectable Adult Primary Liver Cancer;   Recurrent Adult Primary Liver Cancer
Interventions: Drug: sorafenib tosylate;   Other: placebo;   Other: laboratory biomarker analysis
5 Recruiting Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer
Conditions: Adult Primary Hepatocellular Carcinoma;   Advanced Adult Primary Liver Cancer;   Localized Unresectable Adult Primary Liver Cancer;   Recurrent Adult Primary Liver Cancer
Interventions: Drug: doxorubicin hydrochloride;   Drug: sorafenib tosylate
6 Not yet recruiting Tivozanib in Treating Patients With Liver Cancer That is Metastatic or Cannot be Removed by Surgery
Conditions: Adult Primary Hepatocellular Carcinoma;   Advanced Adult Primary Liver Cancer;   Localized Unresectable Adult Primary Liver Cancer;   Recurrent Adult Primary Liver Cancer
Interventions: Drug: tivozanib;   Other: pharmacological study;   Other: laboratory biomarker analysis
7 Recruiting MK2206 in Treating Patients With Advanced Liver Cancer That Did Not Respond to Previous Therapy
Conditions: Adult Primary Hepatocellular Carcinoma;   Advanced Adult Primary Liver Cancer;   Localized Unresectable Adult Primary Liver Cancer;   Recurrent Adult Primary Liver Cancer
Interventions: Drug: Akt inhibitor MK2206;   Other: laboratory biomarker analysis
8 Recruiting Radiation Therapy With Sorafenib for TACE-Resistant Hepatocellular Carcinoma
Conditions: Hepatocellular Carcinoma;   Hepatocellular Cancer;   Hepatoma;   Liver Cancer
Interventions: Drug: Sorafenib;   Radiation: Conventional fractionation (2 Gy per day) external beam radiation therapy
9 Recruiting ADH-1, Gemcitabine Hydrochloride and Cisplatin in Treating Patients With Metastatic Pancreatic or Biliary Tract Cancer That Cannot Be Removed By Surgery
Conditions: Acinar Cell Adenocarcinoma of the Pancreas;   Adenocarcinoma of the Gallbladder;   Adult Primary Cholangiocellular Carcinoma;   Advanced Adult Primary Liver Cancer;   Cholangiocarcinoma of the Gallbladder;   Duct Cell Adenocarcinoma of the Pancreas;   Localized Unresectable Adult Primary Liver Cancer;   Periampullary Adenocarcinoma;   Recurrent Adult Primary Liver Cancer;   Recurrent Gallbladder Cancer;   Recurrent Pancreatic Cancer;   Stage II Gallbladder Cancer;   Stage III Pancreatic Cancer;   Stage IIIA Gallbladder Cancer;   Stage IIIB Gallbladder Cancer;   Stage IV Pancreatic Cancer;   Stage IVA Gallbladder Cancer;   Stage IVB Gallbladder Cancer
Interventions: Drug: ADH-1;   Drug: cisplatin;   Drug: gemcitabine hydrochloride;   Other: laboratory biomarker analysis
10 Recruiting 6,8-Bis(Benzylthio)Octanoic Acid in Treating Patients With Advanced or Metastatic Bile Duct Cancer That Cannot Be Removed By Surgery
Conditions: Adult Primary Cholangiocellular Carcinoma;   Advanced Adult Primary Liver Cancer;   Cholangiocarcinoma of the Extrahepatic Bile Duct;   Cholangiocarcinoma of the Gallbladder;   Localized Unresectable Adult Primary Liver Cancer;   Metastatic Extrahepatic Bile Duct Cancer;   Recurrent Adult Primary Liver Cancer;   Recurrent Extrahepatic Bile Duct Cancer;   Unresectable Extrahepatic Bile Duct Cancer
Intervention: Drug: 6,8-bis(benzylthio)octanoic acid
11 Recruiting Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer
Conditions: Adult Primary Hepatocellular Carcinoma;   Advanced Adult Primary Liver Cancer;   Endometrial Papillary Serous Carcinoma;   Localized Unresectable Adult Primary Liver Cancer;   Metastatic Gastrointestinal Carcinoid Tumor;   Ovarian Carcinosarcoma;   Ovarian Endometrioid Adenocarcinoma;   Ovarian Mixed Epithelial Carcinoma;   Ovarian Papillary Serous Carcinoma;   Pancreatic Alpha Cell Adenoma;   Pancreatic Alpha Cell Carcinoma;   Pancreatic Beta Islet Cell Adenoma;   Pancreatic Beta Islet Cell Carcinoma;   Pancreatic Delta Cell Adenoma;   Pancreatic Delta Cell Carcinoma;   Pancreatic G-cell Adenoma;   Pancreatic G-cell Carcinoma;   Pancreatic Polypeptide Tumor;   Pulmonary Carcinoid Tumor;   Recurrent Adult Primary Liver Cancer;   Recurrent Endometrial Carcinoma;   Recurrent Fallopian Tube Cancer;   Recurrent Gastrointestinal Carcinoid Tumor;   Recurrent Islet Cell Carcinoma;   Recurrent Ovarian Epithelial Cancer;   Recurrent Primary Peritoneal Cavity Cancer;   Regional Gastrointestinal Carcinoid Tumor;   Stage IIIA Endometrial Carcinoma;   Stage IIIA Fallopian Tube Cancer;   Stage IIIA Ovarian Epithelial Cancer;   Stage IIIA Primary Peritoneal Cavity Cancer;   Stage IIIB Endometrial Carcinoma;   Stage IIIB Fallopian Tube Cancer;   Stage IIIB Ovarian Epithelial Cancer;   Stage IIIB Primary Peritoneal Cavity Cancer;   Stage IIIC Endometrial Carcinoma;   Stage IIIC Fallopian Tube Cancer;   Stage IIIC Ovarian Epithelial Cancer;   Stage IIIC Primary Peritoneal Cavity Cancer;   Stage IV Fallopian Tube Cancer;   Stage IV Ovarian Epithelial Cancer;   Stage IV Primary Peritoneal Cavity Cancer;   Stage IVA Endometrial Carcinoma;   Stage IVB Endometrial Carcinoma;   Uterine Carcinosarcoma
Interventions: Drug: temsirolimus;   Biological: bevacizumab
12 Unknown † Evaluation of Intra-operative Ultrasound Contrast Enhancement in the Evaluation of Liver Tumors
Condition: Liver Tumors
Intervention: Drug: Definity®
13 Recruiting Dasatinib in Treating Patients With Advanced Liver Cancer That Cannot Be Removed by Surgery
Conditions: Adult Primary Hepatocellular Carcinoma;   Advanced Adult Primary Liver Cancer;   Recurrent Adult Primary Liver Cancer
Intervention: Drug: dasatinib
14 Recruiting Chemoembolization With or Without Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery
Conditions: Adult Primary Hepatocellular Carcinoma;   Localized Unresectable Adult Primary Liver Cancer;   Recurrent Adult Primary Liver Cancer
Interventions: Drug: sorafenib tosylate;   Other: placebo;   Drug: doxorubicin hydrochloride;   Drug: doxorubicin-eluting beads;   Drug: cisplatin;   Drug: mitomycin C
15 Recruiting A Treatment of Unresectable Hepatocellular Carcinoma With TheraSphere®
Conditions: Liver Tumors;   Hepatocellular Carcinoma;   Hepatoma;   Neoplasms
Intervention: Device: TheraSphere®
16 Recruiting Sorafenib Therapy Prior to Radiofrequency Ablation for Intermediate Sized Hepatocellular Cancer
Condition: Hepatocellular Cancer
Interventions: Drug: Sorafenib or Placebo;   Procedure: Radiofrequency Ablation
17 Unknown † Cyclophosphamide, Radiation Therapy, and Poly ICLC in Treating Patients With Unresectable, Recurrent, Primary, or Metastatic Liver Cancer
Conditions: Breast Cancer;   Colorectal Cancer;   Gastric Cancer;   Liver Cancer;   Melanoma (Skin);   Metastatic Cancer;   Ovarian Cancer;   Pancreatic Cancer
Interventions: Drug: cyclophosphamide;   Drug: poly ICLC;   Procedure: hepatic artery embolization;   Radiation: 3-dimensional conformal radiation therapy
18 Recruiting Transarterial Chemoembolization Using Doxorubicin Beads With or Without Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery
Condition: Liver Cancer
Interventions: Drug: doxorubicin-eluting beads;   Drug: sorafenib tosylate;   Other: laboratory biomarker analysis;   Other: pharmacogenomic studies;   Other: pharmacological study;   Procedure: quality-of-life assessment
19 Recruiting Microwave Ablation of Resectable Liver Tumors
Conditions: Hepatocellular Carcinoma;   Liver Cancer
Intervention: Device: Microwave Ablation
20 Recruiting Phase II Trial of Tivozanib in Advanced Hepatocellular Cancer
Condition: Hepatocellular Cancer
Intervention: Drug: Tivozanib
To Top

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
† Indicates status has not been verified in more than two years